期刊名称：INTERNATIONAL IMMUNOPHARMACOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome.
The subject material appropriate for submission includes:
Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders.
Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state.
Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses.
Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action.
Agents that activate genes or modify transcription and translation within the immune response.
Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active.
Production, function and regulation of cytokines and their receptors.
Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.
Studies on the nature and function of drug and hormone receptors on lymphocytes and other cells in the immune system. Studies of cell-derived or humoral factors that modify the immune system causing cytotoxicity, inducing antibody production and mediating inflammatory responses.
The development of immunologically based assays and their application to disease, including assays for drugs, hormones, cyclic nucleotides, tumor antigens, etc.
The Editors will be pleased to receive published books for possible independent review.
Instructions to Authors
Submission of manuscripts
Online submission of papers
The preferred mechanism of submission of Manuscripts is electronic, by using the ElSubmit submission tool at http://www.elsubmit.com/submit/intimpsubmit. After registration, authors will be asked to upload their article and associated artwork. The submission tool will generate a PDF file to be used for the reviewing process. The submission tool generates an automatic reply which incorporates the manuscript number for future correspondence.
Full instructions on how to use the online submission tool are available at the above web address.
For those authors who cannot submit via ElSubmit, please follow the instructions to authors as shown below.
Send one original and three copies of the text and one original set of figures along with three copies to the editorial office:
International Immunopharmacology
attn. James E. Talmadge
University of Nebraska Medical Center
987660 Nebraska Medical Center
Omaha, NE 68198-7660
U.S.A.
Authors must include a cover letter that contains the title, authors, a brief outline of the work's originality, desired section of publication, corresponding author's name, address, telephone and fax numbers (including country and city codes), and e-mail address.
Authors are encouraged to provide the names, addresses, e-mail addresses and fax numbers of up to four researchers qualified to review the manuscript.
Original materials will be discarded one month following publication unless return is requested.
Submission of manuscripts on disk
Authors are required to submit a computer diskette (3.5 inch HD/DD) to the editorial office when the manuscript is first submitted following these guidelines:
¡¤ Specify software, including release, e.g. Word Office 97).
¡¤ Specify platform (PC or Mac).
¡¤ Include the text file and separate table and illustration files.
¡¤ The file should be single-spaced and should use the wrap-around, end-of-the-line feature (i.e. no return at the end of each line). All textual elements should begin flush left; no paragraph indents. Place two returns after every element such as title, headings, paragraphs, figure and table call-outs.
¡¤ Keep a back-up disk for reference and safety.
¡¤ When your paper has been refereed, revised if necessary and accepted, send a disk containing the final version with the final hard copy. Verify that the disk and hard copy match exactly.
Preparation of manuscripts
¡¤ Manuscripts should be concisely written in English and typed double-spaced throughout on letter-size or A-4 paper with margins of at least 2.5 cm.
¡¤ Each manuscript must have a title page, which includes only the title, the authors' names, and laboratory of origin, the name and address of the person to whom proofs should be mailed, and any necessary footnotes. The title should be as short as is consistent with clarity.
¡¤ Pages should be numbered in succession, the title page being page 1.
¡¤ Tables and figures should be on separate pages placed at the end of the manuscript.
¡¤ Footnotes to the text should be used sparingly; where they must be used superscript numbers should indicate their locations. Footnotes should be typed with corresponding numbers on a separate sheet. In Tables, reference to footnotes should be made using superscript letter.
¡¤ Simple chemical compounds should be named in the text of the Materials and Methods and Results sections by formulae when these can be printed in single horizontal lines of type.
¡¤ Isotopic specifications should conform to the IUPAC system (Biochem. J. (1975) 145, 1-20).
¡¤ Drug names should be the official or approved names; trade names or common names may be given in brackets where the drug is first mentioned. The manufacturer's name and address must be given. The doses of the drugs should be given as unit weight/unit body weight, e.g. mmol/kg or mg/kg. Concentrations should be given in terms of molarity (eg. nM or uM), or as unit weight/unit volume solution (eg. mg/l) stating whether the weight refers to the salt or the active component of the drug. The molecular weight, inclusive of water of crystallization, should be stated if doses are given as unit weight.
¡¤ The IUB Enzyme Commission (EC) number must be quoted with the full name of the enzyme when it is first mentioned in the text. Subsequently the accepted trivial name shall be used, e.g. Full Name: Acetyl-CoA:choline O-acetyltransferase (EC 2.3.1.6.) Trivial Name: Choline acetyltransferase not choline acetylase. For this information the author should refer to Enzyme Nomenclature (1973), Elsevier, Amsterdam.
¡¤ Authors are requested to follow the IUPHAR Guidelines for Classification of New Receptor Subtypes (see Immunopharmacology, Vol. 30, p. 189 or p. 255).
¡¤ Symbols for physical units should be restricted to the Systeme Internationale (S.I.) Units. Examples of commonly used symbols can be found in Biochemical Journal 145, 1-20 (1975) and more detailed description, in Quantities, Units and Symbols (1971) The Royal Society, London.
¡¤ The excessive use of abbreviations in the text is strongly discouraged. In particular, awkward and unfamiliar abbreviations and those intended to express concepts or experimental techniques will not be permitted. In order to aid communication between scientists of different disciplines, authors should only use abbreviations sparingly and should always define the abbreviation when first used by placing it in parentheses after the full term, e.g. fetal bovine serum (FBS).
Organization of manuscript
¡¤ Each paper must begin with an Abstract that summarizes the results obtained and the conclusions drawn. It should not exceed 250 words.
¡¤ A short list of keywords or phrases (3-6) should be supplied following the abstract.
¡¤ An Introduction should first "set the scene" for a non-specialist and then continue with the specific reasons for undertaking the investigation. Exhaustive reviews of the literature should be avoided and no attempt should be made to indicate the results obtained.
¡¤ Materials and Methods. Procedures used should be given in sufficient detail to permit the repetition of the work by others. However, published procedures should be briefly summarized and only described in detail if they have been substantially modified. Special chemicals, drugs, etc. with their sources of supply should be grouped under a separate subheading, Materials.
¡¤ Results. In this section the findings should be described without discussion of their significance. Subsections should be used to clarify the expression of the results.
¡¤ Discussion. In this section the authors' interpretations of their findings should be accompanied by an assessment of their significance in relation to previous work. Subsections should be used wherever possible.
¡¤ References. Only papers closely related to the author's work should be cited. Follow the Vancouver format. References should be cited in the text as Arabic numerals in square brackets and listed numerically in the order of citation at the end of the text. All authors should be cited if six or fewer; if more than six, list the first five and et al. Abbreviations for titles of medical journals should conform to Index Medicus. References should include the names of all authors, title of article, chapter or book, journal name, the year, volume and first and last pages. For a book include the names of any editors, the city and name of publisher. Examples for an article in a journal (a) or book chapter (b) or for a book (c) are:
Guide for Authors
International Immunopharmacology
General
International Immunopharmacology is an interdisciplinary journal devoted to the publication of original scientific papers interrelating immunology and pharmacology. Manuscripts will be considered for publication on the condition that the results reported are based on original research that has not been published elsewhere in any journal or language. Upon acceptance for publication of an article in International Immunopharmacology, the author tacitly agrees to make available any materials used in the published experiments, or novel or natural products disclosed in the article that are not commercially available, so that qualified investigators may confirm the observations. Neither abstracts nor posters that have been presented at scientific meetings and symposia are considered prior publications. Submissions are assumed to be on behalf of all authors and their respective institutes. The Journal will publish the following types of publications:
Commentary. Topical editorials, commentaries, prospective reviews and hypotheses demonstrating acceptable standards of originality. Such articles will only be published following an invitation to the author(s) from the Editor(s). Other prospective authors should obtain editorial permission before submitting a manuscript. Commentaries (3000-10,000 words) will serve as the means for expressing controversial, critical and often personal evaluations of research trends. Commentaries in the form of prospective reviews or hypotheses will be composite presentations of wide-ranging observations from the literature, which should indicate, and possibly stimulate, new directions for potentially rewarding immunopharmacological research.
The Regulatory Reports section will provide a repository of standards for cytokines/chemokines/etc., as well as a forum for thoughts, ideas, and recommendations on toxicology and pathology of immunoregulatory molecules. This section will also track items receiving RAC and IND approval (in the United States) and their counterparts elsewhere.
Rapid Reports. Short, complete studies of such scientific importance that they merit rapid publication. If the editors conclude that a paper does not qualify as a Rapid Report, it will be considered for publication as a full-length manuscript. Rapid Reports are generally two to four journal pages in length, including illustrations and tables. Authors should submit Rapid Reports to either Editor-in-Chief and include a cover letter that indicates the author's wish that it be considered as a Rapid Report and briefly outline why the work merits rapid publication.
Full-length articles are full-length descriptions of original research. Scope may include basic science, clinical results, or applications. These manuscripts will undergo standard review and normally are not expedited.
Reviews are comprehensive appraisals of research and clinical outcomes in a field of current interest. All reviews are subject to the normal review process. Consult with either Editor-in-Chief regarding content and length prior to submission.
Book Reviews. Books for review may be sent to James E. Talmadge. Authors interested in reviewing a particular book should communicate directly with him.
Preliminary Studies/Reports. This section is for the publication of new observations that are promising but have not achieved the stature of a regular article, yet are judged by the reviewers or editorial staff to contribute a novel, important, or useful observation worthy of publication. These reports, including clinical studies on a limited patient population, will generally be brief reports of a single or a few observations or results comprising up to four printed pages including all references and display items; appropriate statistical analyses should be included.
Natural Products contributions must meet the following specific criteria: a) any natural extract should be defined, and appropriate information provided regarding the origin; and b) the author must be able to state that the material under study is endotoxin free.
Meeting/Symposia reports are synopses of meetings and symposia, generally shorter than five journal pages. Please contact either Editor-in-Chief prior to submitting. Reports must be submitted within two weeks of the end of the meeting.
Special Thematic Reports are collections of full-length articles and/or reviews on a specific topic.
Correspondence is a forum for presentation of preliminary clinical data, technology changes, and case reports. Letters extending or disputing claims published in previous issues of the Journal are encouraged. They will be forwarded to the original authors for written comment. Both opinions will be published concurrently. Limited correspondence relating only to articles previously published in the International Immunopharmacology will be considered for publication at the discretion of the Editors.
Submission of manuscripts
Online submission of papers
The preferred mechanism of submission of Manuscripts is electronic, by using the ElSubmit submission tool at http://www.elsubmit.com/submit/intimpsubmit. After registration, authors will be asked to upload their article and associated artwork. The submission tool will generate a PDF file to be used for the reviewing process. The submission tool generates an automatic reply which incorporates the manuscript number for future correspondence.
Full instructions on how to use the online submission tool are available at the above web address.
For those authors who cannot submit via ElSubmit, please follow the instructions to authors as shown below.
Send one original and three copies of the text and one original set of figures along with three copies to the editorial office:
International Immunopharmacology
attn. James E. Talmadge
University of Nebraska Medical Center
987660 Nebraska Medical Center
Omaha, NE 68198-7660
U.S.A.
Authors must include a cover letter that contains the title, authors, a brief outline of the work's originality, desired section of publication, corresponding author's name, address, telephone and fax numbers (including country and city codes), and e-mail address.
Authors are encouraged to provide the names, addresses, e-mail addresses and fax numbers of up to four researchers qualified to review the manuscript.
Original materials will be discarded one month following publication unless return is requested.
Submission of manuscripts on disk
Authors are required to submit a computer diskette (3.5 inch HD/DD) to the editorial office when the manuscript is first submitted following these guidelines:
Specify software, including release, e.g. Word Office 97).
Specify platform (PC or Mac).
Include the text file and separate table and illustration files.
The file should be single-spaced and should use the wrap-around, end-of-the-line feature (i.e. no return at the end of each line). All textual elements should begin flush left; no paragraph indents. Place two returns after every element such as title, headings, paragraphs, figure and table call-outs.
Keep a back-up disk for reference and safety.
When your paper has been refereed, revised if necessary and accepted, send a disk containing the final version with the final hard copy. Verify that the disk and hard copy match exactly.
Preparation of manuscripts
Manuscripts should be concisely written in English and typed double-spaced throughout on letter-size or A-4 paper with margins of at least 2.5 cm.
Each manuscript must have a title page, which includes only the title, the authors' names, and laboratory of origin, the name and address of the person to whom proofs should be mailed, and any necessary footnotes. The title should be as short as is consistent with clarity.
Pages should be numbered in succession, the title page being page 1.
Tables and figures should be on separate pages placed at the end of the manuscript.
Footnotes to the text should be used sparingly; where they must be used superscript numbers should indicate their locations. Footnotes should be typed with corresponding numbers on a separate sheet. In Tables, reference to footnotes should be made using superscript letter.
Simple chemical compounds should be named in the text of the Materials and Methods and Results sections by formulae when these can be printed in single horizontal lines of type.
Isotopic specifications should conform to the IUPAC system (Biochem. J. (1975) 145, 1-20).
Drug names should be the official or approved names; trade names or common names may be given in brackets where the drug is first mentioned. The manufacturer's name and address must be given. The doses of the drugs should be given as unit weight/unit body weight, e.g. mmol/kg or mg/kg. Concentrations should be given in terms of molarity (eg. nM or uM), or as unit weight/unit volume solution (eg. mg/l) stating whether the weight refers to the salt or the active component of the drug. The molecular weight, inclusive of water of crystallization, should be stated if doses are given as unit weight.
The IUB Enzyme Commission (EC) number must be quoted with the full name of the enzyme when it is first mentioned in the text. Subsequently the accepted trivial name shall be used, e.g. Full Name: Acetyl-CoA:choline O-acetyltransferase (EC 2.3.1.6.) Trivial Name: Choline acetyltransferase not choline acetylase. For this information the author should refer to Enzyme Nomenclature (1973), Elsevier, Amsterdam.
Authors are requested to follow the IUPHAR Guidelines for Classification of New Receptor Subtypes (see Immunopharmacology, Vol. 30, p. 189 or p. 255).
Symbols for physical units should be restricted to the Systeme Internationale (S.I.) Units. Examples of commonly used symbols can be found in Biochemical Journal 145, 1-20 (1975) and more detailed description, in Quantities, Units and Symbols (1971) The Royal Society, London.
The excessive use of abbreviations in the text is strongly discouraged. In particular, awkward and unfamiliar abbreviations and those intended to express concepts or experimental techniques will not be permitted. In order to aid communication between scientists of different disciplines, authors should only use abbreviations sparingly and should always define the abbreviation when first used by placing it in parentheses after the full term, e.g. fetal bovine serum (FBS).
Organization of manuscript
Each paper must begin with an Abstract that summarizes the results obtained and the conclusions drawn. It should not exceed 250 words.
A short list of keywords or phrases (3-6) should be supplied following the abstract.
An Introduction should first "set the scene" for a non-specialist and then continue with the specific reasons for undertaking the investigation. Exhaustive reviews of the literature should be avoided and no attempt should be made to indicate the results obtained.
Materials and Methods. Procedures used should be given in sufficient detail to permit the repetition of the work by others. However, published procedures should be briefly summarized and only described in detail if they have been substantially modified. Special chemicals, drugs, etc. with their sources of supply should be grouped under a separate subheading, Materials.
Results. In this section the findings should be described without discussion of their significance. Subsections should be used to clarify the expression of the results.
Discussion. In this section the authors' interpretations of their findings should be accompanied by an assessment of their significance in relation to previous work. Subsections should be used wherever possible.
References. Only papers closely related to the author's work should be cited. Follow the Vancouver format. References should be cited in the text as Arabic numerals in square brackets and listed numerically in the order of citation at the end of the text. All authors should be cited if six or fewer; if more than six, list the first five and et al. Abbreviations for titles of medical journals should conform to Index Medicus. References should include the names of all authors, title of article, chapter or book, journal name, the year, volume and first and last pages. For a book include the names of any editors, the city and name of publisher. Examples for an article in a journal (a) or book chapter (b) or for a book (c) are:
a) Maldonado-Lopez R, De Smedt T, Michel P, Godfroid J, Pajak B, et al. CD8a+ and CD8a- subclases of dendritic cells direct the development of distinct T helper cells in vivo. J.Exp Med 1999; 189: 587-592.
b) Gullick WJ and Venter DJ. The c-erbB2 and its expression in human tumours. In: Waxman J, Sikora K, editors. The molecular biology of cancer. Oxford: Blackwell Scientific Publications, 1989; p. 38-53.
c) Lumley JSP, Green CJ, Lear P, Angell-James JE. Essentials of experimental surgery. London: Butterworths, 1990.
Unpublished experiments, papers in preparation, and personal communications may be mentioned only in the text; they may not be listed in the list of references. A paper that has been accepted for publication but not yet published may be included in the list of References. In the citation, replace year, volume and page numbers with "In press". The date of acceptance should be indicated when submitting the paper.
Figure legends. Each figure must have a legend. Include all legends together in one section, each on a separate page.
Tables. Each table must be on a separate page and together with its caption and legend, be self-explanatory.
Figures. Each figure must be numbered with the authors' names and International Immunopharmacology written on the back. The figure together with its legend should be self-explanatory. Photomicrographs should be prepared using these guidelines: For micrographs to be printed to the edge of the page, the prints should fill a space 155 mm wide and up to 200 mm long. To allow for trimming, important material and lettering should not occur within 10 mm of the edge. The authors should directly label micrographs. For other half tones (including color plates), the maximum area available is 155 X 210 mm. The authors should also directly label these prints. A charge is made for reproducing color photographs; the cost will be given on request. Final lettering of Figures will be done by the Publisher if the lettering desired is indicated in soft pencil. Figures lettered in India ink will be accepted if the lettering is of high standard and large enough to be legible when the Figures are reduced to the final size. Symbols on graphs etc. should be inserted by the author using standard characters.
Submission of Rapid Reports
Manuscripts submitted for consideration as a Rapid Report should present scientifically sound and novel research in a clear and concise fashion and contain conclusions of unusual interest to immunologists and pharmacologists that are justified by the data presented. Chief criteria for acceptance are scientific novelty and quality, originality, conciseness and clarity.
Manuscripts submitted as a Rapid Report should conform to the additional guidelines listed below as well as to the information for authors for full-length manuscripts discussed above. Rapid Report submissions are reviewed rapidly (normally within a few weeks). Only minor revisions are permitted because of time constraints. Brief reviewer comments may be provided to authors.
The maximum length of Rapid Report articles is usually four printed pages. However, at the discretion of the Editor, this may be extended to six printed pages.
¡¤ Rapid Report submissions require four copies of the manuscript; all gray scale images should be submitted as publication-quality prints. In addition to hard copies of the manuscript, Rapid Report authors are also required to submit a 3.5" computer disk containing an electronic version of the text and figures. The figures must also be provided electronically.
¡¤ Add "Attention: Rapid Report" to the mailing label, and mail the manuscript to either Editor-in-Chief.
¡¤ Rapid Report articles, including figures and references must fit within four journal pages. Authors should estimate the size of the figures and tables and limit the text accordingly.
¡¤ The abstract is limited to 150 words.
¡¤ The Materials and Methods section may be sharply limited which should be sufficient to allow the evaluation of results and conclusions.
¡¤ Authors may choose to fuse the Results and Discussion sections.
¡¤ Given the constraints of rapid publication and use of the author's electronic file to typeset the article, no proofs will be provided for Rapid Reports.
Proofs
One set of proofs will be supplied for the author to check for typesetting accuracy, to be returned to the publisher within 3 days of receipt. No changes to the original manuscript will be allowed at this stage.
Authors can keep track of the progress of their accepted article, and set up e-mail alerts informing them of changes to their manuscript's status, by using the "Track a Paper" feature of Elsevier's Author Gateway. Offprints
Twenty-five offprints of each accepted paper will be supplied to the corresponding author at no cost. Additional offprints will be available by ordering on the reprint order form.
Transfer of Copyright
All authors must sign the 'Transfer of Copyright' agreement before the article can be published. This transfer agreement enables Elsevier Science Ltd to protect the copyrighted material for the authors, but does not relinquish the author's proprietary rights. The copyright transfer covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature and translations, and includes the right to adapt the article for use in conjunction with computer systems and programs, including reproduction or publication machine-readable form and incorporation in retrieval systems. If excerpts (for example figures) from copyrighted works are included the author is responsible for obtaining written permission from the copyright holder prior to submitting the final version of the paper. Full credit must be given to such sources.
Editorial Board
Editorial Board
Editor-in-Chief:
J.E. Talmadge, University of Nebraska Medical Center, 987660 Nebraska Medical Center, Omaha, NE 68198-7660, USA.
Fax: +1 402-559-4990
Email:jtalmadg.ImmPharm@atlarge.net
T.E. Hugli, California Toxicology Research Institute, 1989 Palomar Oaks Way, Carlsbad, CA 92009, USA.
Fax: +1 760-929-9834
Email:thugli@CTRI-NP.org
Associate Editors:
F. Pearce, University College London, Dept. of Chemistry, 20 Gordon Street, London, WC1H 0AJ, United Kingdom. Tel. +44 171 387 7050; Fax: +44 171 380 7463; E-mail: f.l.pearce@ucl.ac.uk
|
